If pharma DTC spending in the final quarter of 2009 continues at the average rate during the first three quarters, the total spend in 2009 will be about $4.7 billion, a 7.1% increase over 2008 (see chart below).
NOTE: TNS MI looks only at measured media, including: Network TV; Spot TV (122 DMAs); Cable TV (71 networks); Syndication TV; Hispanic Network TV (4 networks); Consumer Magazines (231 publications); Sunday Magazines (7 publications); Local Magazines (22 publications); Hispanic Magazines (14 publications); Business-to-Business Magazines (278 publications); Local Newspapers (143 publications); National Newspapers (3 publications); Hispanic Newspapers (47 publications); Network Radio (5 networks); Spot Radio; Local Radio (32 markets); Internet (DISPLAY advertising only, not search engine advertising, which can be 40% of the total Internet ad spend); and Outdoor. Figures do not include public service announcement (PSA) data.
I had predicted a further decrease in DTC spending in 2009 (see "DTC Spending Will Be Decimated in 2009, Experts Say") and this can still happen because the 0.6% increase so far is pretty slim. If Q4 spending is only $716 million instead of the $1,161 million estimated to create the chart above, then my prediction will come true.
Speaking of predictions, I have a new survey: Predicting the Future of the Drug Industry: 2010 and Beyond! Among the predictions I am seeking opinions on is this one:
Internet-based drug promotion (including search engine marketing) will overtake TV-based DTC in the U.S. in terms of dollars spent (by 2019).TNS MI reported a 7% increase in Internet display advertising in the first nine months of 2009 vs same period in 2008. Meanwhile there was an 11.5% decrease in network TV advertising during that period and a Q3 spending tumble of 25.1%. Pharma Internet display ad spending more than tripled in the nine-month period to $221 million according to DTC Perspectives.
Even doubling that figure to account for search engine advertising, the amount that pharma spends on the Internet vs TV is miniscule ($221 + $200 million for SEM = $421 for total Internet ad spend first 9 months; Internet portion of spending pie = 12% vs 60% for TV).
Is it possible, therefore, for Internet ad spending by pharma to exceed TV ad spending by 2019? Well, about 56% of respondents to my survey think it is somewhat or highly likely to happen!
What do you think? Please take my survey now. The survey also asks your opinion about the following predictions:
- New follow-on biologics legislation in the U.S. will increase competition from generic equivalents and eventually decrease brand profits
- Broadcast (ie, TV) Direct-to-Consumer (DTC) drug promotion will be banned or sharply curtailed by law in the U.S.
- The European Union will finally allow Direct-to-Consumer (DTC) advertising to its citizens
- Due to decreasing effectiveness of traditional physician detailing and rise of non-personal detailing, the role of traditional sales representative will become obsolete
- New healthcare reform legislation will dramatically increase the sales of drugs in the U.S.
- Extensive outcomes data available to payers and comparative effectiveness research will force the industry much further down the path of pay-for-performance (ie, adopt a more flexible approach to pricing)
- Patients will become even more influential and empowered in making healthcare decisions as they are forced to pay a larger share of costs and/or have access to health information from a variety of sources
- Despite lack of innovative new drugs and/or generic competition, sales of brand drugs worldwide will show a sharp increase due to increased demand in emerging markets (eg, China)
- More efficient targeting of drugs and marketing to specific patient populations6 will greatly increase effectiveness and decrease side effects of drugs
- Social media marketing7 will become a significant part (>10%) of the pharmaceutical marketing mix
- The next BIG opportunity for targeted marketing to patients and physicians is mobile apps on "smart phones"
- Pharmaceutical and biotech companies will continue to increase their outsourcing of clinical trials and related drug development. Outsourcing will account for more than 50% of R&D spending by 2019.